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Abstract
Introduction: Fine-needle aspiration biopsy (FNAB) is regarded as the gold standard method for the diagnosis of thyroid nodules, but it 
has its limitations. Additional methods that would improve sensitivity and specificity in the diagnosis of thyroid cancer (TC), especially 
in indeterminate lesions. Molecular tests seem to be such a tool. BRAF V600E mutation (the most common in TC) can be detected in FNAB 
and can be potentially a very useful ancillary marker for FNAB practice. 
The aim of our study was to evaluate the usefulness of the detection of the BRAF V600E mutation in FNAC in the early diagnosis of TC in 
patients with indeterminate cytology.
Material and method: 2290 FNAB were performed and 147 indeterminate results (group 3, 4, and 5 of the Bethesda system) were obtained. 
Material from these groups was submitted for molecular tests for the occurrence of BRAF V600E mutation. Sensitivity, specificity, positive 
predictive value, negative predictive value, and accuracy of the tests were calculated. 
Results: Determining the presence of BRAF V600E mutation in FNAC material in groups 3 and 4 together and in group 5 is associated with 
sensitivity of TC diagnosis of 37.5% and 81.8%, respectively. In all cases the detection of BRAF V600E mutation was associated with histo-
pathologically proving the presence of TC (specificity of the test — 100%).
Conclusions:
1. The presence of BRAF V600E mutation in FNAC material is always associated with the presence of TC.
2. The usefulness of determining the presence of BRAF V600E in FNAC in cytological groups 3 and 4 is associated with low sensitivity in 
the diagnosis of thyroid cancer.
3. Due to its high specificity BRAF V600E study may be useful in determining the scope of surgery in patients in cytological group 5. 
(Endokrynol Pol 2016; 67 (1): 41–47)
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Streszczenie
Wstęp: Biopsja aspiracyjna celowana cienkoigłowa (BACC) jest uznawana za złoty standard w diagnostyce guzków tarczycy. Ma ona 
jednak swoje ograniczenia. Poszukiwane są więc dodatkowe metody, które poprawiłyby czułość i specyficzność diagnozowania raka 
tarczycy, zwłaszcza w przypadku zmian niezdeterminowanych w BACC. Badania molekularne wydają się być takim narzędziem. 
Mutacja BRAF V600E (najczęstsza w raku tarczycy) może być wykrywana w materiale z biopsji i może wspomagać BACC w rozpozna-
waniu raka tarczycy.
Celem pracy była ocena przydatności wykrywania mutacji BRAF V600E w BACC w zmianach niezdeterminowanych we wczesnej diagno-
styce pacjentów ze zmianami ogniskowymi w tarczycy.
Materiał i metody: Przeprowadzono 2290 BACC, uzyskując w 147 próbkach wyniki niezdeterminowane (grupy 3, 4 i 5 wg klasyfikacji 
Bethesda). W grupie tej przeprowadzono badania molekularne w kierunku występowania mutacji BRAF V600E. Obliczono czułość, swoistość, 
wartość predykcyjną dodatnią, wartość predykcyjną ujemną i dokładność testu.
Wyniki: Obecność mutacji BRAF V600E w grupach cytologicznych 3 i 4 łącznie oraz w grupie 5 wiązała się z czułością w rozpoznawaniu 
raka tarczycy odpowiednio 37,5% i 81,8%. W każdym przypadku wykrycia mutacji BRAF V600E w badaniu pooperacyjnym rozpoznano 
raka tarczycy (specyficzność testu —100%).
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testing aimed at the identification of BRAF V600E mutation 
was performed in the patients with cytological group 3, 
4, and 5. Written, informed consent was obtained from 
each patient prior to the study. 
Fine-needle aspiration biopsy (FNAB)
Fine-needle aspiration biopsy was obtained by a pa-
thologist under ultrasonographic (US) guidance of 
a radiologist. Either the radiologist or the pathologist 
was certified to perform the thyroid biopsies. Neck 
ultrasonography was performed with the use of de-
vices featuring a colour Doppler function: Siemens 
Versa pro and Hitachi EUB-6500, with a high frequency 
linear probe (7.5 MHz). The smears were obtained by 
using 27-gauge needles fitted to a 2-mL syringe. In 
each case, two smears were prepared and fixed in 86% 
ethanol and stained with H-E stain. In our institution 
a minimum of six clusters of 10 epithelial cells must be 
found on two smears, based on two separate aspira-
tions, for the specimen to be considered satisfactory. 
These smears were evaluated according to the Bethesda 
system. Most of the material (about two thirds) from 
the biopsy needle was used for cytological examina-
tion. The remaining material was stored frozen for 
potential further molecular examination. Only patients 
with Bethesda cytological results in groups 3, 4, and 
5 were submitted to molecular tests for occurrence of 
BRAF V600E mutation.
DNA isolation 
The material for the isolation of DNA was washed 
from the needle after the FNAC obtained with 500 ul 
of the phosphate buffer. DNA was isolated using the 
Micro Genomic Blood AX Gravity (A & A Biotechnol-
ogy, Gdańsk, Poland) according to the manufacturer’s 
instructions. For cytological smears DNA isolation was 
performed using a DNA FFPE Kit (Qiagen) according 
to the manufacturer’s instructions.
Test used for detection of BRAF V600E mutation
The following tests were used to detect BRAF V600E mu-
tation: Sanger sequencing with sensitivity of 10–20% 
of mutated alleles in combination with allele-specific 
PCR (ASA-PCR) with a sensitivity of 5% of mutated 
alleles (from 1.10.2013 to 31.03.2014) and qPCR (from 
Wnioski:
1. Obecność mutacji BRAF V600E w materiale BACC jest zawsze związana z obecnością RT.
2. Przydatność określenia obecności BRAF V600E w BACC w grupach cytologicznych 3 i 4 jest związana z niską czułością rozpoznania RT.
3. Ze względu na wysoką specyficzność BRAF V600E badania mogą być przydatne w określaniu zakresu operacji u pacjentów z grupy 
cytologicznej 5. (Endokrynol Pol 2016; 67 (1): 41–47)
Słowa kluczowe: BRAF V600E; rak tarczycy; BACC
Study was funded and supported by Holycross Cancer Centre.
Introduction
The incidence of thyroid nodules detected by ultra-
sonography (US) exceeds 50% in the adult population 
[1]. Most of them are benign and only 1–5% turn out to 
be thyroid cancer [2]. The incidence of thyroid cancer 
is increasing globally, as well as in Poland where it has 
quintupled over the past 20 years [3]. Fine-needle aspi-
ration biopsy (FNAB) is regarded as the gold standard 
method for the diagnosis of thyroid nodules (TN), but it 
has its limitations — for example, inadequate specimens 
or indeterminate results. This occurs in approximately 
15–30% of cases [4]. Consequently there is increasing 
demand for an accurate initial diagnosis of TN to avoid 
unnecessary operation and to correctly and quickly 
qualify the patient for the operation. More than 80% 
of TCs are papillary thyroid cancers (PTC) [5]. A point 
mutation of BRAF V600E results in consecutive activation 
of serine/threonine kinase RAF type B and the whole 
signalling pathway of MAPK (MAPK kinase), which is 
important in the process of oncogenesis in the develop-
ment of TC. The BRAF V600E mutation frequency ranges 
from 30 to 80% of cases of PTC [2, 6]. BRAF V600E mutation 
can be detected in FNAC, and potentially can be a very 
useful ancillary marker for FNAC practice. 
The aim of our study was to evaluate the usefulness 
of the detection of the BRAF V600E mutation in FNAC in 
the early diagnosis of TC in patients with indeterminate 
cytology (Bethesda groups 3, 4, and 5) in a population 
with high prevalence of BRAF V600E mutation in TC. 
Material and methods
Patients
1590 patients were examined (1375 females and 215 
males; mean age 51.6 ± 12.6 years) from October 2013 
to October 2014, and there were 2290 FNABs performed. 
Patients were qualified for biopsy from the Endocri-
nology Outpatient Clinic in Holycross Cancer Centre, 
Kielce, Poland according to “AACE/AME/ETA medical 
guidelines for clinical practice and management of thy-
roid nodules” [7] and according to “Diagnosis and treat-
ment of thyroid cancer — Polish guidelines” [8]. The 
smears were evaluated according to Bethesda Thyroid 
Cytology Classification (Bethesda system). Molecular 
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1.04.2014 to 30.09.2014) with a sensitivity of about 1%. 
Finally each genetic sample was examined with a highly 
sensitive method. The change of method during the 
study was caused by the diagnostic capabilities of our 
genetics department.
Details concerning molecular techniques have previ-
ously been described in detail elsewhere [9, 10]
Sequencing
We used the following PCR primers: BRAFek15f 
5’-TCATAATGCTTGCTCTGATAGGA-3’ and BRAFek15r 
5’-GGCCAAAAATTTAATCAGTGGA-3’ for the ampli-
fication of 224 bp of DNA segment containing codon 
600 of BRAF. Sequencing was performed using ABI 
3130 Automatic Capillary DNA Sequencer and BigDye 
Terminator v1.1 Cycle Sequencing kit (Life Technolo-
gies, Warsaw, Poland) according to the manufacturer’s 
instruction (Fig. 1 A–C).
Allele–specific PCR
Allele–specific PCR was performed using the BRAFek15f, 
BRAFek15r, and a p.V600E mutation–specific primer 
and (BRAFek15mutA 5‘-GGTGATTTTGGTCTAGC-
TACAGA-3’) primers. The BRAFek15f and BRAFek15r 
create a 224bp control band, and BRAFek15mutA with 
BRAF15r create a mutation band of 126bp. When the 
control band was not visible, the results were uninter-
pretable (Fig. 2).
qPCR
A qPCR assay targeting 68 bp of BRAF exon 15 was 
performed using Rotor-Gene Q (Qiagen, Syngen-
Biotech, Poland) with the following probes: BRAFmut 
(6FAM-CTACAGAGAAATC-MG-BNFQ), BRAF-WT 
(VIC-CTACAGTGAAATC-MGB-NFQ) and primers: for-
ward 5‘ agacctcacagtaaaaataggtgattttgg 3‘ and reverse 
5‘ gatgggacccactccatcg 3‘ (Fig. 3).
Statistical analysis
In order to define clinically performed molecular 
tests in the group of patients with indeterminate 
Figure 1. Examples of the results of Sanger Sequencing: A. The BRAF V600E mutation; B. Inconclusive; C. Wild type — WT
Rycina 1. Przykłady wyników sekwencjonowania Sangerowskiego: A. Mutacja BRAF V600E; B. Wynik niejednoznaczny; C. WT
A B C 
cytology (Bethesda group 3, 4, 5) the obtained results 
were defined as: 1. true positive (TP) — the presence 
of BRAF V600E mutation in FNAB and post-operation 
confirmed thyroid cancer; 2. true negative (TN) — 
neither BRAF V600E mutation found nor evidence of 
malignancy in post-operative histopathology nor the 
lack of a malicious nature of the changes found in the 
patients who were not operated on but left under 
active observation the observation period was from 
6 months to 12 months; 3) false positive (FP) — con-
firmed BRAF V600E in the absence of confirmation of 
cancer in post-operative material; and 4) false nega-
tive (FN) — absence of BRAF V600E in FNAB and the 
confirmation of TC in the post-operative material. This 
enabled the determination of: sensitivity, specificity, 
positive predictive value, negative predictive value, 
and accuracy of the used method.
For statistical analysis the results of group 3 and 
4 were combined because the diagnosis of the risk of 
cancer occurrence is lower than in the fifth group. In 
addition, further proceedings in groups 3–4 are similar: 
either observation can be considered or diagnostics 
operation (usually to remove the lobe with isthmus). 
However, with cytological diagnosis in group 5 — the 
treatment of choice is surgery of the total (total thy-
roidectomy) or partial removal of the thyroid gland 
(subtotal thyroidectomy). 
The obtained results (sensitivity, specificity, positive 
predictive value PPV, negative predictive value NPV, 
and accuracy) were given in percentages and its 95% 
confidence intervals (CI) were calculated. The software 
used for calculations was MEDCALC (www.medcalc.
org/calc/diagnostic_test.php) 
Results
2290 cytological smears were obtained from 1590 con-
secutive patients. Obtained cytological results were 
classified according to Bethesda system. In cytological 
group: 1 (nondiagnostic or unsatisfactory) there were 
163 (7.12%) smears; 2 benign — 1965 (85.8%), 3 — AUS/ 
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/FLUS (atypia of undetermined significance or follicular 
lesion of undetermined significance) — 106 (4.63%); 
4 — FN/SFN (follicular neoplasm or suspicion for a fol-
licular neoplasm) — 29 (1.27%); 5 — SFM (suspicious 
for malignancy) — 12 (0.5%), 6 — malignant 15 (0.66%). 
147 indeterminate results were obtained (Bethesda 
groups 3, 4, 5). Material from these groups was submit-
ted for molecular tests for the occurrence of BRAF V600E 
mutation. BRAF V600E was revealed in only 12 nodules 
(3 in cytological group 3 and 9 in cytological group 5).
Figure 3. Genotyping BRAF V600E mutation using qPCR. black colour — no template control sample, the green colour — the control 
sample without the BRAF V600E mutation, red — the control sample with mutations in the BRAF V600E, blue colour — samples tested
Rycina 3. Genotypowanie mutacji BRAF V600E za pomocą metody qPCR. Kolor czarny — próbka kontrolna bez matrycy, Kolor 
czerwony — próbka kontrolna bez mutacji BRAF V600E, kolor czerwony — próbka kontrolna z mutacją BRAF V600E, kolor niebieski 
— próbki badane
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Figure 2. Genotyping BRAF V600E mutation using ASA-PCR 
method. Visualisation by chip electrophoresis Multina (Shimadzu, 
Japan). X1 — weight marker, C8 — no template control, C9 — 
negative control — sample without the BRAF V600E mutation 
— WT, C10 — negative control sample without mutation, C11 
— control sample with BRAF V600E mutation; C12, E1, E2 and 
E3 tested samples. 224pz - reaction control band, 126pz — band, 
BRAF V600E mutation
Rycina 2. Genotypowanie mutacji BRAF V600E za pomocą 
metody ASA-PCR. Wizualizacja za pomocą elektroforezy chipowej 
Multina (Shimadzu, Japan). X1 — marker masy, C8 — kontrola 
bez matrycy, C9 — kontrola, próbka bez mutacji BRAF V600E, 
C10 — próbka kontrolna bez mutacji, C11 — próbka kontrolna z 
mutacją BRAF V600E; C12, E1, E2 i E3 próbki badane. 224pz — 
prążek kontrolny reakcji, 126pz — prążek świadczący o obecności 
mutacji BRAF V600E
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In cytological group 3 (AUS/FLUS) there were 
106 smears: 103 with wild type and 3 with BRAF V600E 
mutation. Out of the 103 patients without the BRAF V600E 
mutation 62 were operated on, and in post-operative 
pathological examination nodular goitre (NG) was 
revealed in 59 patients, in 2 FTC, and PTC in 1. PTC, 
however, was an accidental discovery: a papillary micro 
carcinoma of 4 mm dimension was found in a patient 
with a NG — a lesion that was not subjected to biopsy. 
All three remaining patients with BRAF V600E mutation 
were operated on. On histopathological examination, 
in two of them classical variant of PTC (cvPTC) and in 
one follicular variant of PTC (fvPTC) were revealed.
In cytological group 4 (FN/SFN) there were no BRAF 
V600E mutations revealed. Twenty out of 29 patients from 
this group were operated on because of the clinical sta-
tus of the tumours. Postoperatively: two patients had 
FTC, and the remaining 18 had nodular goitre (NG). 
Forty-one patients from group 3 and 9 patients from 
group 4 were not operated on — and left for active ob-
servation (repeated FNAC or US) — without evidence 
of thyroid cancer during follow-up from 6 to 12 months.
In cytological group 5 (SFM) there were 12 patients 
— all of them according to guidelines were operated 
on (diagnostic operation). Nine of them had BRAF 
V600E mutation. Postoperatively cvPTC was revealed in 
this group of patients. In the remaining three patients 
with wild type: diagnosis of fvPTC was seen in one, 
anaplastic thyroid carcinoma in one, and NG in one 
patient was established after the operation. 
Fifty patients were left under active observation. In 
the TP group there were 12 patients (3 from group 3 and 
9 from group 5). In the TN group there were 127 patients 
(41 not operated on and 59 operated on from group 3; 
9 not operated on and 18 operated on from group 4). 
There were no FP patients in the examined group — all 
patients with preoperative diagnosis of BRAF V600E in 
FNAC had confirmed thyroid cancer postoperatively. In 
the FN group there were five patients (three from group 
3 [2-FTC and 1 PTC] and two with FTC from group 4). 
All of the results are presented in Figure 4.
Based on the obtained results of sensitivity, speci-
ficity, PPV, NPV, and accuracy were calculated for the 
occurrence of BRAF V600E mutation — together for groups 
3 and 4 and for group 5. The results are shown in Table I.
Determining the presence of BRAF V600E mutation 
in FNAC material in groups 3 and 4 together and in 
group 5 is associated with sensitivity of TC diagnosis of 
37.5% and 81.8%, respectively. In all cases the detection 
of BRAF V600E mutation was associated with histopatho-
logically proving the presence of TC (specificity of the 
test — 100%).
Discussion
In the era of wide availability of US, thyroid lesions 
are more often recognised. It is estimated that in the 
adult population, more than 50% of thyroid lesions 
are detected by ultrasound [1]. Thyroid cancer oc-
curs in only approx. 1–5% of the total amount of the 
changes shown by ultrasound examination [2]. FNAC 
performed under US guidance is still the best method 
to diagnose TC. However, it has limitations referring 
to, in particular, follicular lesions (cytological group 
3 and 4) and lesions suspected of malignancy (cytologi-
cal group 5) according to Bethesda Thyroid Cytology 
Figure 4. Study scheme and results. cvPTC — classical variant 
of papillary thyroid carcinoma, fvPTC — follicular variant of 
papillary thyroid carcinoma, FTC — follicular thyroid carcinoma, 
NG — nodular goitre, ATC — anaplastic thyroid carcinoma
Rycina 4. Schemat badania i wyniki. cvPTC — wariant klasyczny 
raka brodawkowatego, fvPTC — wariant pęcherzykowy raka 
brodawkowatego, FTC — rak pęcherzykowy, NG — wole guzkowe, 
ATC — rak anaplastyczny
Table I. Determining the presence of BRAF V600E mutation in fine-needle aspiration cytology
Tabela I. Określenie obecności mutacji BRAF V600E w biopsji aspiracyjnej cienkoigłowej
Cytological group Sensitivity 95% (CI) Specificity 95% (CI) PPV 95% (CI) NPV 95% (CI) Accuracy 95% (CI)
Group 3 + 4 37.5%
0.123–0.375
100%
0.984–1.000
100%
0.984–1.000
96.2%
0.947–0.962
96.3%
0.933–0.963
Group 5 81.8%
0.732–0.818
100%
0.056–1.000
100%
0.895–1.000
33.3%
0.019–0.333
83.3%
0.676–0.833
CI — confidence intervals; PPV — positive predictive value; NPV — negative predictive value
CYTOLOGY
GROUP 3
GROUP 4
GROUP 5
No of SAMPLES
106
29
12
BRAFV600E
3
103
29
9
3
HISTOLOGY
2cvPTC, 1fvPTC
1cvPTC, 2FTC, 59 NG
18NG, 2FTC
9cvPTC
1fvPTC, 1ATC, 1NG
ACTIVE 
OBSERVATION
41
9
+
–
–
+
–
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Classification [4]. In the case of cytological group 3, 
repeated FNAC under US guidance is recommended 
within 3–12 months and a possible diagnostic opera-
tion is advisable. In the case of cytological group 4 
diagnostic operations (usually subtotal thyroidectomy) 
are recommended to be considered. However, in the 
case of cytological group 5 a diagnostic operation — 
total or subtotal thyroidectomy — is recommended 
[8]. Unnecessary operations (benign histology) occur 
most frequently in patients with cytological groups 
3 and 4 because of the low prevalence of TC in these 
groups (10–25% in group 3 and 15–30% in group 4) 
[11]. Additional methods that would improve sensi-
tivity and specificity in diagnosis of TC, especially in 
indeterminate lesions. Molecular tests seem to be such 
a tool. More than 80% of thyroid cancers are PTC, and 
the most common genetic alteration in PTC is BRAF 
V600E. Its frequency ranges from 30 to 80% of cases of 
PTC — in the Polish population it occurs in 68–70 % 
of PTC [9, 12, 13]. Because of the high prevalence of 
this mutation it was feasible to use BRAF mutation in 
FNAC as a marker of TC in our study.
The prevalence of BRAF V600E mutation in thyroid 
cancer depends on different factors: geographic area, 
ethnicity, and iodine consumption [14, 15]. It is much 
higher in Korea - present in 80% of PTC [16], while it 
occurs only in 30–50% in Western countries [2, 15]. The 
prevalence of BRAF V600E mutation depends on the type 
of thyroid cancer. It occurred in about 80-100% of tall 
cell variant (rare variant of PTC), in 45–68% of classical 
variant (most frequent), and in up to 12–18% (15%) of 
follicular variant of PTC [17, 18]. BRAF V600E mutation 
can occasionally be present in lymphoma as well as 
anaplastic thyroid carcinoma. 
Sensitivity markers of BRAF V600E mutation in ma-
terial obtained from FNAB in the diagnosis of TC in 
different studies range from about 32% (Cohen [19]) 
to 82 % (Kim [20]). 
The cited works differ in groups of patients evalu-
ated with the use of molecular techniques: the pro-
portion of PTC in the whole group TC and the way 
of assessing analysis of sensitivity referring to PTC or 
to all TC. In the Kim study the molecular tests were 
performed in 961 patients with a high risk of TC. 
Sonographically the thyroid lesions characterised as 
suspicious or indeterminate features. FNAC was not 
performed in sonographically benign lesions. As many 
as 181 (18.3%) FNACC results were in group 6, and 
postoperatively on histopathology in 180 cases of PTC 
[162 BRAF V600E (+), and among BRAF V600E (–): 18-PTC 
and in one-MTC] were revealed. This is probably the 
reason for such high sensitivity: 82.5% obtained in this 
study [20]. A high (75%) sensitivity was also obtained 
in detection of BRAF V600E mutation in the study by Jo et 
al. In this study there were prospectively evaluated 101 
thyroid nodules with FNAB (43 benign, 30 malignant, 24 
indeterminate or suspicious, 4 nondiagnostic). On final 
histopathological diagnosis PTC occurred in 54 patients 
(from cytological groups malignant and indeterminate). 
Among 30 of them BRAF V600E(+) mutation was present 
in 22 patients with cytological group 6 (malignant), in 
7 indeterminate nodules, and in 1 from the non diag-
nostic cytology group [21]. 
Slightly lower sensitivity (63.5%) in detection of 
BRAF V600E in detecting PTC was revealed in the Zatelli 
study. For molecular analysis, in the study 469 thy-
roid lesions with sonographic features of malignancy 
were enrolled. Lesions were of relatively small size: 
1.1 ± 0.8 cm. Only the recognition of PTC was analysed. 
Simultaneous determination of the presence of BRAF 
V600E mutation and FNAC increased the sensitivity of cy-
tology for PTC from 77% to 87% [22]. In Xing’s analysis 
the presence of BRAF V600E mutation was performed in 
patients previously submitted for operations based on 
clinical and sonographic features, and FNACC results 
obtained a sensitivity of 50% [23]. 
In the case of separation cytological indeterminate 
group (3, 4, 5) the sensitivity of the method differs 
significantly — mostly in cytological group 3. In the 
study by Lee et al. among 325 smears suspicious for 
malignancy (SFM) — 205 (63,1%) smears were BRAF 
(+), while in the case of AUS/FLUS only 37 smears 
among 353, which means 10.5% had BRAF (+) muta-
tion [24].
In the presented study the sensitivity of the used 
method was slightly higher. The total for cytological 
groups 3 and 4 was 37.5%, and for group 5 it was 81.8%. 
It should be emphasised that in the presented 
study in group 4 BRAF V600E mutation was not revealed 
in any of the cases. This can be connected with the 
low prevalence of PTC in this cytological category 
and higher prevalence of FTC that are BRAF V600E 
negative. Moreover, in all the studies it was high-
lighted that high positive predictive value in the 
detection of cancer can reach 100% [25–27]. Results 
from the presented study are concordant with cited 
reports. In all of the patients with mutation BRAF V600E 
detected in FNAC, postoperatively the diagnosis of 
TC was established. PPV was 100% for all the exam-
ined cytological groups.
It is highlighted that molecular tests have to be 
adapted to the prevalence of cancer in different cyto-
logical categories in different medical centres. So the 
decision to conduct a test for the presence of BRAF 
mutation — initially dictated by financial considerations 
and availability – seems to be right.
Detection of BRAF V600E mutation is associated with 
a specificity of 100% in the detection of cancer. Most 
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of the TC are PTC, of which about are BRAF V600E posi-
tive. These cancers are usually accurately diagnosed 
in cytology and are most commonly qualified to cyto-
logical group 6, and more rarely to cytological group 
5 (in our centre postoperative histology reveals TC in 
81% of cases). Because of the very high prevalence of 
TC in this cytological group it is standard procedure 
to carry out thyroidectomy or diagnostic lobectomy 
in case of a single nodule. The detection of BRAF V600E 
mutation in each case resulted in the making of the 
decision about the total thyroidectomy. Prevalence of 
cancer in cytological groups 3 and 4 is low, and ad-
ditionally in these cytological groups FTC are usually 
present (in this type of cancer BRAF V600E mutation 
is absent), or follicular variant of PTC (with lower 
prevalence of BRAF V600E mutation), which limits the 
usefulness of the detection of the mutation in the 
diagnosis of TC. In the presented study two cases 
of undiagnosed TC (BRAF V600E negative) in groups 
3 and 4 referred to FTC. In group 5 one undiagnosed 
TC turned out to be fvPTC (BRAF V600E negative) and 
one anaplastic cancer. 
Conclusions
1. The presence of BRAF V600E mutation in FNAC mate-
rial is always associated with the presence of TC.
2. The usefulness of determining the presence of 
BRAF V600E in FNAC in cytological groups 3 and 4 
is associated with low sensitivity in diagnosis of 
thyroid cancer.
3. Due to its high specificity BRAF V600E study may be 
useful in determining the scope of surgery in pa-
tients in cytological group 5.
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